PIK3CA and melanoma: Given the accurate predictive power of the PI3K pathway mutation for immunotherapy in HNSC, we further explored its significance in other common tumors based on pan-cancer genomic data and immunotherapy information from the MSKCC-2019 cohort (esophagogastric cancer and colorectal cancer) and MSKCC-2014 cohort (melanoma).